All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.
Introducing
Now you can personalise
your AML Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe AML Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the AML Hub cannot guarantee the accuracy of translated content. The AML Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Bookmark this article
During the 46th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT), the AML Hub spoke to Arnon Nagler, Vice Chair of the Acute Leukaemia Working Party of the EBMT. We asked, Which is more relevant for allo-HSCT outcome: cytogenetic risk or MRD status?
Which is more relevant for allo-HSCT outcome: cytogenetic risk or MRD status?
In this video, Arnon Nagler talks about the role of measurable residual disease (MRD) compared with cytogenetic risk in allogeneic hematopoietic stem cell transplant (allo-HSCT) in patients with AML. Traditionally, leukemic risk defined the prognosis of AML, which was in turn determined by the presence of cytogenetic lesions. However, in recent years, MRD has become increasingly important.
Subscribe to get the best content related to AML delivered to your inbox